Zoetis (NYSE:ZTS) and ANI Pharmaceuticals (NASDAQ:ANIP) Head-To-Head Comparison

ANI Pharmaceuticals (NASDAQ:ANIP) and Zoetis (NYSE:ZTS) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends and risk.

Volatility and Risk

ANI Pharmaceuticals has a beta of 0.45, suggesting that its share price is 55% less volatile than the S&P 500. Comparatively, Zoetis has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500.

Valuation and Earnings

This table compares ANI Pharmaceuticals and Zoetis”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANI Pharmaceuticals	$883.37 million	1.76	$78.34 million	$5.02	13.50
Zoetis	$9.47 billion	3.59	$2.67 billion	$5.88	13.97

Zoetis has higher revenue and earnings than ANI Pharmaceuticals. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

76.0% of ANI Pharmaceuticals shares are held by institutional investors. Comparatively, 92.8% of Zoetis shares are held by institutional investors. 8.1% of ANI Pharmaceuticals shares are held by insiders. Comparatively, 0.2% of Zoetis shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares ANI Pharmaceuticals and Zoetis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals	11.07%	27.37%	10.47%
Zoetis	27.49%	74.89%	18.59%

Analyst Ratings

This is a summary of current ratings and target prices for ANI Pharmaceuticals and Zoetis, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANI Pharmaceuticals	0	4	3	0	2.43
Zoetis	1	12	8	0	2.33

ANI Pharmaceuticals currently has a consensus price target of $100.00, indicating a potential upside of 47.51%. Zoetis has a consensus price target of $101.25, indicating a potential upside of 23.22%. Given ANI Pharmaceuticals’ stronger consensus rating and higher possible upside, equities analysts clearly believe ANI Pharmaceuticals is more favorable than Zoetis.

Summary

Zoetis beats ANI Pharmaceuticals on 11 of the 14 factors compared between the two stocks.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

About Zoetis

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.